Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 46 unusual trades.Delving into the details, we found 41% of traders were bullish, while 32% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $616,686, and 41 were calls, valued at $2,414,792.Predicted Price RangeTaking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 减肥药市场的蓬勃发展，推动了 礼来公司 （ Eli Lilly ） 成为 首家市值突破 1 万亿美元 的制药企业 ，从而跻身于主要由科技公司组成的万亿美元俱乐部，成为 第 10 家市值突破万美元公司，其他9 家分别是英伟达 （4.35 万亿美元） 、苹果 （4 万亿美元） 、 Alphabet （3.6 万亿美元） 、 微软 （3.5 万亿美元） 、 值得一提的是， 礼来公司近期与美国政府达成协议，为部份患者降低 替尔泊肽 价格，以价格换取销量增长。 除了减肥药物之外， 投资者还看好 礼来公司的 抗 癌药物 Verzenio （ CDK4/6抑制剂，主要用于乳腺癌治疗，2024 年销售额已达 53 亿美元 ） 和治疗银屑病药物 Taltz （ IL-17A抑制剂，2024 年销售额已达 32 亿美元 ） 的持续销售增长，以及礼来公司在其他领域 （例如阿尔茨海默病和心血管疾病） 的研发潜力。 本周五，礼来公司的股价一度涨至 1061.17 美元，使其市值 超过 1 万亿美元 。相比之下，目前市值第二高药企 强生公司 为 4700 亿美元 ，另一款畅销减肥药 司美格鲁肽的开 ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Eli Lilly. ...

Core Insights - Eli Lilly has shown a strong recovery in its stock performance, catching up with the S&P 500 year to date, driven by solid clinical results and impressive quarterly earnings [1][2] Financial Performance - Eli Lilly's revenue for the latest quarter reached $17.6 billion, representing a 54% increase compared to the same period last year, showcasing exceptional growth for a pharmaceutical company [4] - The company's non-GAAP earnings per share were reported at $7.02, a staggering 495% increase year-over-year [4] - Tirzepatide, marketed as Mounjaro and Zepbound, generated $10.1 billion in revenue for the quarter, more than doubling from Q3 2024 [5] - The company has raised its revenue guidance for fiscal year 2025 to between $63 billion and $63.5 billion, up from a previous estimate of $60 billion to $62 billion, indicating a projected year-over-year growth of 40.6% at the midpoint [5] Market Position and Growth Opportunities - Eli Lilly is focusing on the weight management market, with promising results from phase 3 clinical trials for orforglipron, an oral GLP-1 candidate, which is expected to receive approval by early next year [7][8] - The company is also developing retatrutide, which could provide deeper and more rapid weight loss compared to existing obesity treatments [10] - In oncology, Eli Lilly's breast cancer drug Verzenio generated $1.5 billion in sales, a 7% increase from the previous year, and the company received approval for a new breast cancer therapy, Inluriyo [12] - Eli Lilly is partnering with Nvidia to create a large AI supercomputer aimed at improving drug development processes, which could enhance efficiency and reduce costs in the long run [13][14]

Core Viewpoint - Eli Lilly's revenue growth is significantly driven by its weight loss drugs Mounjaro and Zepbound, indicating strong market performance and potential for future growth [6][7]. Financial Performance - Eli Lilly's revenue is projected to increase by 54% in Q3 2025, rising from $11.439 billion in 2024 to $17.6 billion [6]. - Mounjaro's revenue grew by 109%, from $3.112 billion to $6.515 billion, while Zepbound's revenue surged by 185%, from $1.257 billion to $3.588 billion [6]. - The company raised its annual earnings per share forecast to $23.70, up from $23.00, exceeding the initial prediction of $21.75 [6]. Market Position - Eli Lilly leads the weight loss market with its dual agonists Mounjaro and Zepbound, which target both GIP and GLP-1, compared to Novo Nordisk's single GLP-1 agonist Wegovy [7]. - Analysts express caution regarding a potential "GLP-1 bubble," highlighting risks from emerging competitors and market saturation [7]. Manufacturing Expansion - Eli Lilly plans to build a new $3 billion manufacturing facility in Katwijk, Netherlands, to enhance its production capacity for oral medications [9]. - The new plant will focus on orforglipron, an oral GLP-1 receptor agonist, with FDA approval expected by mid to late 2026 [9]. - The facility is anticipated to create 500 high-paying jobs and approximately 1,500 jobs during construction [9]. Regulatory and Strategic Initiatives - Eli Lilly is preparing for orforglipron's approval and is investing heavily in U.S. manufacturing, aligning with the trend of domestic drug production emphasized by the Trump administration [10]. - The company has not yet reached a pricing agreement with the White House, unlike competitors such as Pfizer and AstraZeneca [10]. Clinical Development - Orforglipron has shown promising results in four Phase III clinical trials, demonstrating effectiveness in blood sugar control and weight loss [11]. - The drug may represent a significant breakthrough as it does not require injections and could be priced lower than injectable alternatives [11]. - Eli Lilly plans to submit an FDA application for orforglipron by the end of 2025, potentially accelerating the approval process through the National Priority Voucher program [11].

Group 1 - The primary goal for long-term retail investors is to build wealth over an extended period to achieve financial goals such as secure retirement or buying a home [1] - Asset allocation is essential for diversification and long-term success, requiring investments across different asset classes like stocks, bonds, and cash [2] Group 2 - Eli Lilly (NYSE: LLY) develops and manufactures drugs across various therapeutic areas, including notable products like cancer drug Verzenio and diabetes drug Jardiance, with a strong pipeline in oncology, immunology, and neuroscience [4] - Eli Lilly is expanding the use of its GLP-1 drugs for new conditions and developing next-generation therapies, including orforglipron, a once-daily oral GLP-1 agonist expected to be submitted for regulatory approval by the end of 2025 [5][6] - The company is also working on retatrutide, an injectable triple-agonist, with promising phase 2 results for weight loss, and late-stage results expected before the end of 2025 [7]

Core Insights - Eli Lilly and Company (LLY) reported third-quarter 2025 adjusted earnings per share (EPS) of $7.02, exceeding the Zacks Consensus Estimate of $6.02 per share, and significantly up from $1.18 per share in the same quarter last year [1][9] - Revenues reached $17.60 billion, a 54% increase year over year, driven by strong sales of GLP-1 drugs, Mounjaro and Zepbound, surpassing the Zacks Consensus Estimate of $16.01 billion [2][9] Revenue and Sales Performance - Mounjaro sales were $6.52 billion, up 109% year over year, beating the Zacks Consensus Estimate of $5.48 billion [3] - Zepbound recorded sales of $3.59 billion, a 185% increase year over year, exceeding the Zacks Consensus Estimate of $3.45 billion [4] - Trulicity generated revenues of $1.05 billion, down 19% year over year, in line with estimates [6] - Jardiance sales rose 40% to $959 million, surpassing the Zacks Consensus Estimate of $687 million [6] - Taltz brought in sales of $901.5 million, up 2% year over year, but missed the Zacks Consensus Estimate [7] - Verzenio generated sales of $1.47 billion, up 7% year over year, but also missed estimates [7] - Emgality revenues were $175.7 million, down 13% year over year, while Olumiant sales were $268.9 million, up 7% [8] Market Dynamics and Competition - Mounjaro and Zepbound are gaining market share from Novo Nordisk's Ozempic and Wegovy, despite facing strong competition [5] - The company is investing in obesity treatments and has several new molecules in clinical development, including orforglipron and retatrutide [14] Guidance and Future Outlook - Lilly raised its 2025 revenue guidance to $63.0 billion to $63.5 billion, up from a previous range of $60.0 billion to $62.0 billion, and increased EPS guidance to $23.00 to $23.70 [11][13] - The company is expanding its portfolio beyond GLP-1 drugs into cardiovascular, oncology, and neuroscience areas, with recent acquisitions to enhance its pipeline [17][18] Stock Performance - Following the strong third-quarter results and guidance increase, Lilly's shares rose more than 5% in pre-market trading, with a year-to-date increase of 5.3% compared to the industry average of 3.3% [13]

Financial Data and Key Metrics Changes - In Q3 2025, revenue grew by 54% compared to Q3 2024, driven by key products [6][9] - Gross margin as a percentage of revenue was 83.6%, an increase of 1.4 percentage points year-over-year [9] - Earnings per share increased to $7.02, compared to $1.18 in Q3 2024 [10] Business Line Data and Key Metrics Changes - Revenue from key products accounted for $12 billion in the quarter, with significant contributions from immunology, oncology, and cardiometabolic health [11][12] - EBGLYSS prescriptions increased by 41% in Q3 2025 compared to Q2 2025 [11] - Mounjaro's total prescriptions grew by over 60% in the U.S. [14] Market Data and Key Metrics Changes - U.S. revenue increased by 45%, with strong volume growth from Zepbound and Mounjaro, despite a 15% decline in price [10] - International revenue increased by over 100% in constant currency, reflecting strong uptake of Mounjaro [10] - Japan, China, and the rest of the world saw constant currency revenue growth of 24%, 22%, and 51%, respectively [10] Company Strategy and Development Direction - The company is focused on expanding its manufacturing footprint and has announced plans for new facilities in the U.S. [7][8] - Lilly aims to leverage its robust pipeline and R&D investments to maintain a competitive edge in the market [51][53] - The company is pursuing an "all of the above" strategy to expedite the launch of orforglipron [39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong performance and market share gains in the incretin analogs market [6][9] - The company raised its revenue and earnings per share guidance for the year based on strong financial performance [6][15] - Management acknowledged the competitive landscape but emphasized confidence in their portfolio and execution strategy [51][53] Other Important Information - The company distributed $1.3 billion in dividends and executed approximately $700 million in share repurchases during the quarter [8] - Lilly achieved several key milestones, including FDA approvals and positive trial results for multiple products [7][26] Q&A Session Summary Question: Comments on orforglipron and its market launch - Management indicated a focus on getting orforglipron to patients quickly and is pursuing various strategies to expedite its launch [39] Question: Insights on Mounjaro's international ramp - Management noted strong performance in new markets and emphasized the importance of patient activation for obesity treatment [46] Question: Market dynamics and competitor behavior - Management expressed confidence in their competitive position and highlighted ongoing investments in R&D and execution [51][53] Question: Pricing and volume dynamics for orforglipron - Management discussed the importance of understanding price elasticity and the potential for significant market expansion with orforglipron [85]

Core Insights - Eli Lilly and Co. reported better-than-expected third-quarter earnings, leading to an increase in stock price and an upward revision of its annual forecast [1][8] Financial Performance - Quarterly revenue reached $17.60 billion, a 54% year-over-year increase, surpassing the consensus estimate of $16.02 billion, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices [2] - Adjusted earnings per share were reported at $7.02, significantly up from $1.18 a year ago, exceeding the consensus of $5.70 [3] - Key Products revenue grew to $11.98 billion in Q3 2025, primarily driven by Mounjaro and Zepbound [2] Product Performance - Mounjaro's revenue increased by 109% to $6.52 billion, with U.S. revenue at $3.55 billion, reflecting a 49% increase [4] - Zepbound revenue surged 184% to $3.57 billion, driven by increased demand [5] - Verzenio revenue rose 7% to $1.47 billion, supported by volume growth [5] Profitability Metrics - Gross profit increased by 57% to $14.59 billion, with a gross margin of 82.9%, up by 1.9 percentage points due to a favorable product mix [5] Future Outlook - The company raised its fiscal year 2025 sales guidance from $60 billion-$62 billion to $63 billion-$63.5 billion, compared to the consensus of $61.65 billion [6] - Adjusted earnings guidance for 2025 was increased from $21.75-$23.00 to $23-$23.70, against a consensus of $22.18 [6] Investment and Expansion Plans - Eli Lilly announced a planned investment of over $1.2 billion to expand and modernize its manufacturing site in Puerto Rico, with construction expected to begin in 2026 [6][7] - The new facility will integrate advanced technologies and expand production capacity for oral solid medicines, including orforglipron, Lilly's first oral weight loss drug [7] - The project is expected to create up to 1,000 construction jobs and 100 high-tech manufacturing positions [8]

Financial Performance - Total revenue reached $17601 million, a 54% increase compared to Q3 2024[12, 17] - Key product revenue grew by 104%, reaching $12 billion[12] - Non-GAAP earnings per share (EPS) increased by $584 to $702[12] - The company raised the midpoint of full-year revenue guidance by over $2 billion[10] Product Highlights - Lilly's U S incretin analogs market share increased to 579% of total prescriptions, with market growth of 36% versus prior year[10, 26] - Mounjaro U S sales were $36 billion, and international sales were $30 billion[56] - Zepbound U S sales were $36 billion, and international sales were $20 million[59] - Verzenio U S sales were $880 million, and international sales were $590 million[62] - Jaypirca Q3 2025 sales were $143 million, with U S TRx increasing 61% vs Q3 2024[24] - Ebglyss Q3 2025 sales were $127 million, with U S TRx growing 41% vs Q2 2025[24] - Omvoh Q3 2025 sales were $65 million[24] - Kisunla Q3 2025 sales were $70 million[24] Strategic Investments - Year-to-date capital investments totaled $53 billion[12] - Research & Development investment was $35 billion, representing 27% of revenue[12] - Marketing, selling & administrative expenses were $27 billion, a 31% increase[12] - $13 billion was distributed via dividends and $07 billion in share repurchases[14] Regulatory and Clinical Updates - Inluriyo (imlunestrant) received U S FDA approval for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer[11] - Kisunla received marketing authorization in Europe for early symptomatic Alzheimer's disease[11] - Orforglipron showed positive results in four additional Phase 3 trials[11] - Jaypirca significantly improved progression-free survival in treatment-naïve CLL/SLL[11]